Background The expanding options in advanced therapies for ulcerative colitis (UC) and
Crohn's disease (CD) present challenges in treatment selection. Persistence analysis …

Background Patients with inflammatory bowel disease (IBD) are at increased risk of
infection. The aim of this study was to assess the cumulative incidence and risk of infection …

Objectives To compare persistence and describe dose titration among bio-naïve patients
with Crohn's disease (CD) initiated on ustekinumab or adalimumab. Methods Bio-naïve …

The real-world evidence data from multiple sources which includes information on patient
health status and medical behavior in routine clinical setup can give deeper insights into …

Inflammatory bowel diseases, comprising Crohn's disease (CD) and ulcerative colitis (UC),
are chronic, relapsing, and remitting immune-mediated inflammatory diseases affecting the …

Introduction The therapeutic armamentarium for managing Crohn's disease (CD) has
expanded significantly in recent decades. Several biologics with three different mechanisms …

Background Therapeutic options for ulcerative colitis (UC) have increased since the
introduction of biologics a few decades ago. Due to the wide range of biologics available …

Objective To estimate long-term persistence among bio-naïve patients with CD initiated on
ustekinumab or adalimumab. Methods Adults with CD initiating ustekinumab or adalimumab …

This meta-analysis has been conducted to compare ustekinumab and adalimumab as
induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD) …